• Temafloxacin Pharmacokinetics: Findings and Relevance

  2026-08-18

  The reference study integrates oral and intravenous pharmacokinetic data to explain temafloxacin exposure, distribution, elimination, and dosing interval selection. Its findings support high oral bioavailability, an approximately 8-hour terminal half-life, and renal-function-based interval adjustment, while offering a useful analytical framework—but not direct dosing evidence—for evaluating chemically distinct agents such as Sulfamonomethoxine.

• GSDMC Drives PDAC Stemness and Immune Evasion

  2026-08-17

  A 2024 Advanced Science study identifies Gasdermin C (GSDMC) as a transcriptionally active regulator of pancreatic ductal adenocarcinoma stemness, metastasis, and immune evasion, independent of classical pyroptosis. The work links ADAM17-dependent cleavage and nuclear GSDMC localization to CXCL9-regulated immune remodeling and suggests that GSDMC targeting may improve responses to KRASG12D inhibition and PD-1 blockade.

• Disodium bicinchoninate in ROS and Cell Assays

  2026-08-16

  Disodium bicinchoninate brings an aqueous, low-organic-solvent option to protein-normalization and chelation workflows supporting inflammatory cell studies. This guide translates the KGN-cell nanoparticle study into practical assay design, with preparation parameters, matrix controls, and troubleshooting strategies.

• HyperFluor™ 488 Rabbit Anti-Goat IgG Workflow

  2026-08-15

  Translate goat-primary immunodetection into bright, flexible readouts for replication-organelle imaging, Western blotting, flow cytometry, and tissue staining. This Alexa Fluor 488 conjugated secondary antibody is especially useful when FXR-associated membrane organization must be compared across cell populations and assay formats.

• PGE2-Driven Schwann Cell Dedifferentiation in PDAC

  2026-08-15

  Wang et al. identify a paracrine PTGES–PGE2 axis that drives Schwann cell dedifferentiation and promotes perineural invasion in pancreatic ductal adenocarcinoma. By combining clinical multi-omics with coculture and three-dimensional functional models, the study connects tumor-derived prostaglandin signaling to Schwann cell remodeling, LIF and ADAMTS-1 secretion, and directional tumor–nerve interactions.

• Individual SGLT2 Inhibitors in Diabetes and Heart Failure

  2026-08-14

  This systematic review and network meta-analysis compared five individual SGLT2 inhibitors in patients with type 2 diabetes and heart failure, rather than treating the drug class as therapeutically uniform. The findings support substantial heart-failure hospitalization reductions across the class while indicating more limited certainty for differences in composite cardiovascular outcomes between individual agents.

• EZ Cap™ Mouse IL-12 mRNA (m1Ψ) Guide

  2026-08-14

  This scenario-driven guide explains how EZ Cap™ Mouse IL-12 mRNA (m1Ψ), SKU R1058, can improve experimental control when researchers assess immune-cell viability, proliferation, or cytotoxicity. It connects transcript design, handling, assay controls, interpretation, and extrahepatic delivery evidence without conflating product specifications with independent performance claims.

• (-)-Arctigenin for NF-κB and MEK1 Workflows

  2026-08-13

  Build reproducible inflammation, signaling, and tumor-microenvironment assays with (-)-Arctigenin, a small-molecule tool spanning iNOS/NF-κB and MEK1-linked experiments. This workflow also shows how to use pharmacological pathway modulation alongside the macrophage EV–miR-660 model without confusing pathway convergence with proof of direct targeting.

• Hypoxia–S100A10 Signaling in Glioblastoma

  2026-08-13

  This study identifies hypoxia-induced S100A10 as a molecular link between the glioblastoma microenvironment, aggressive growth, altered glycolysis, and temozolomide resistance. By integrating public genomic data with cellular proliferation, apoptosis, metabolism, and signaling assays, the work positions S100A10–PI3K-AKT activity as a potential mechanistic axis for further investigation.

• MEDUSA Reveals Hidden Mechanisms of Drug-Induced Death

  2026-08-12

  Honeywell and colleagues introduce MEDUSA, a time-resolved, simulation-assisted framework that separates drug-associated growth effects from cell-death effects in pooled functional genomic screens. Applied to DNA damage, the method identified a p53-dependent switch from apoptosis to a respiration-requiring nonapoptotic death program, showing how death-rate analysis can improve mechanism-of-action and resistance studies.

• RITA (NSC 652287) Assay Workflow Guide

  2026-08-11

  RITA (NSC 652287) combines MDM2-p53 pathway activation with DNA cross-linking activity, making it useful for mechanism-aware cancer studies rather than single-endpoint viability screens. This guide shows how to separate cytostasis from cell death, optimize dose and timing, and connect renal carcinoma research findings with tumor xenograft model design.

• PEI-Modified Laminarin Nanoparticles Enhance OVA Immunity

  2026-08-10

  The reference study developed polyethyleneimine-modified cationic laminarin nanoparticles that combine ovalbumin delivery with adjuvant activity, promoting dendritic-cell activation, lysosomal escape, and antigen cross-presentation. Compared with aluminum adjuvant, the formulation produced stronger antibody and cellular immune responses, although further work is needed to define dose, safety, and translational performance.

• Intravenous Cefazedone PK/PD in CAP

  2026-08-09

  This small prospective study linked intravenous cefazedone exposure with pathogen susceptibility and clinical outcomes in mild to moderate community-acquired pneumonia. Its main contribution was showing that a 2 g every 12 hours regimen produced an average free-drug time above MIC of approximately 55%, supporting regimen rationality while also highlighting the limits of uncontrolled pharmacokinetic evidence.

• Everolimus (RAD001): From Growth Arrest to Cell Death

  2026-08-08

  Everolimus (RAD001) is an mTOR pathway inhibitor whose biological impact can be misread when viability is treated as synonymous with cell death. This guide combines pathway pharmacology with a paired assay framework for distinguishing cancer cell proliferation inhibition, cytostasis, and apoptosis in translational research.

• AMG 487: Practical CXCR3 Antagonist Workflows

  2026-08-07

  AMG 487 is a selective CXCR3 antagonist for dissecting chemokine-driven migration, calcium signaling, and macrophage polarization. Its strongest use-case is a state-aware workflow that combines pharmacology with LAMP1 and autophagy measurements rather than treating CXCR3 signaling as a single, context-independent pathway.

455 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page